The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Amy KangBrendan SmythBrendon L NeuenHiddo J Lambers HeerspinkGian Luca Di TannaHong ZhangClare ArnottCarinna HockhamRajiv AgarwalGeorge L BakrisDavid M CharytanDick de ZeeuwTom GreeneAdeera LevinCarol PollockDavid C WheelerKenneth W MahaffeyVlado PerkovicMeg J JardinePublished in: Diabetes, obesity & metabolism (2023)
Canagliflozin did not affect risk of non-genital SSTIs or non-genital fungal SSTIs compared with placebo. These findings suggest that any SGLT2 inhibitor-mediated change in skin microenvironment is unlikely to have meaningful clinical consequences.